文献速递冠心病血脂与心血管预防

75岁及以上急性冠脉综合征患者辛伐他汀联合依折麦布与辛伐他汀单药治疗的比较:随机临床试验的二次分析

Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2019-01-01

该研究为IMPROVE-IT试验的预设二次分析,比较稳定后急性冠脉综合征(ACS)患者中辛伐他汀联合依折麦布与辛伐他汀单药治疗的效果。结果显示,75岁及以上患者联合治疗的主要终点绝对风险降低最大(8.7%),且不良事件未增加。

要点

  • 75岁及以上ACS患者联合治疗绝对风险降低8.7%,获益最大
  • 联合治疗未增加老年患者不良事件风险
  • 结果可能影响老年人群降脂指南推荐

核心结论

  • ACS住院患者接受辛伐他汀联合依折麦布强化降脂较辛伐他汀单药治疗获益,75岁及以上患者绝对风险降低最大。
  • 老年患者联合依折麦布未显著增加安全性问题。

研究设计与样本

  • IMPROVE-IT试验的预设二次分析,全球多中心前瞻性随机双盲研究。
  • 纳入50岁及以上ACS住院患者,随机接受辛伐他汀联合依折麦布或辛伐他汀加安慰剂,中位随访6年(IQR 4.3-7.1年)。

主要发现

  • ≥75岁患者绝对风险降低8.7%。
  • 年轻及老年患者中联合治疗未增加不良事件发生率。

临床怎么用

  • 对于75岁及以上稳定后的ACS患者,可考虑辛伐他汀联合依折麦布强化降脂以降低心血管事件风险。
  • 老年患者使用联合降脂治疗时安全性良好,无需过度担忧不良事件增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Limited evidence is available regarding the benefit and hazard of higher-intensity treatment to lower lipid levels among patients 75 years or older. As a result, guideline recommendations differ for this age group compared with younger patients. OBJECTIVE: To determine the effect on outcomes and risks of combination ezetimibe and simvastatin compared with simvastatin monotherapy to lower lipid levels among patients 75 years or older with stabilized acute coronary syndrome (ACS). DESIGN, SETTING, PARTICIPANTS: In this prespecified secondary analysis of the global, multicenter, prospective clinical randomized Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), outcomes and risks were compared by age among patients 50 years or older after a hospitalization for ACS. Data were collected from October 26, 2005, through July 8, 2010, with the database locked October 21, 2014. Data were analyzed May 29, 2015, through March 13, 2018, using Kaplan-Meier curves and Cox proportional hazards models. INTERVENTIONS: Double-blind randomized assignment to combined simvastatin and ezetimibe or simvastatin and placebo with follow-up for a median of 6 years (interquartile range, 4.3-7.1 years). MAIN OUTCOMES AND MEASURES: The primary composite end point consisted of death due to cardiovascular disease, myocardial infarction (MI), stroke, unstable angina requiring hospitalization, and coronary revascularization after 30 days. Individual adverse ischemic and safety end points and lipid variables were also analyzed. RESULTS: Of 18 144 patients enrolled (13 728 men [75.7%]; mean [SD] age, 64.1 [9.8] years), 5173 (28.5%) were 65 to 74 years old, and 2798 (15.4%) were 75 years or older at randomization. Treatment with simvastatin-ezetimibe resulted in lower rates of the primary end point than simvastatin-placebo, including 0.9% for patients younger than 65 years (HR, 0.97; 95% CI, 0.90-1.05) and 0.8% for patients 65 to 74 years of age (hazard ratio [HR], 0.96; 95% CI, 0.87-1.06), with the greatest absolute risk reduction of 8.7% for patients 75 years or older (HR, 0.80; 95% CI, 0.70-0.90) (P = .02 for interaction). The rate of adverse events did not increase with simvastatin-ezetimibe vs simvastatin-placebo among younger or older patients. CONCLUSIONS AND RELEVANCE: In IMPROVE-IT, patients hospitalized for ACS derived benefit from higher-intensity therapy to lower lipid levels with simvastatin-ezetimibe compared with simvastatin monotherapy, with the greatest absolute risk reduction among patients 75 years or older. Addition of ezetimibe to simvastatin was not associated with any significant increase in safety issues among older patients. These results may have implications for guideline recommendations regarding lowering of lipid levels in the elderly. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00202878.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Bach RG, Cannon CP, Giugliano RP, et al. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019. PMID: 31314050. doi:10.1001/jamacardio.2019.2306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。